Collplant biotechnologies reports 2025 first quarter financial results and provides a corporate update

- in q1 following a development achievement, collplant received a $2 million payment from abbvie – - advancement of regenerative breast implant program continues; encouraging findings continue to be observed -  rehovot, israel , may 28, 2025 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhcollagen for tissue regeneration and medical aesthetics, today announced financial results for the first quarter of 2025 and provided a corporate update. yehiel tal, collplant's chief executive officer commented, "while advancing our core programs, we've remained disciplined in optimizing costs and prioritizing initiatives that are designed to support a well-capitalized path forward in the best interest of our shareholders.
CLGN Ratings Summary
CLGN Quant Ranking